Veracyte Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
815
- Stock Symbol
-
VCYT
- Investments
-
5
- Share Price
-
$32.84
- (As of Friday Closing)
Veracyte General Information
Description
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
Contact Information
Website
www.veracyte.comCorporate Office
- 6000 Shoreline Court
- Suite 300
- South San Francisco, CA 94080
- United States
Corporate Office
- 6000 Shoreline Court
- Suite 300
- South San Francisco, CA 94080
- United States
Veracyte Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $32.84 | $32.97 | $18.61 - $35.51 | $2.52B | 76.8M | 924K | -$0.75 |
Veracyte Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 1,461,482 | 1,820,585 | 1,549,256 | 2,781,721 |
| Revenue | 399,579 | 361,051 | 296,536 | 219,514 |
| EBITDA | (40,090) | (56,741) | (12,273) | (61,943) |
| Net Income | (54,041) | (74,404) | (36,560) | (75,563) |
| Total Assets | 1,234,327 | 1,114,906 | 1,156,422 | 1,187,825 |
| Total Debt | 20,738 | 12,630 | 14,718 | 18,853 |
Veracyte Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Veracyte Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Veracyte Comparisons
Industry
Financing
Details
Veracyte Competitors (23)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agendia | Venture Capital-Backed | Irvine, CA | ||||
| Foundation Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Centogene | Formerly VC-backed | Rostock, Germany | ||||
| HemoCue | Corporate Backed or Acquired | Ängelholm, Sweden | ||||
| Asuragen | Formerly VC-backed | Austin, TX |
Veracyte Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Veracyte Patents
Veracyte Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3215402-A1 | Methods and systems to identify a lung disorder | Pending | 29-Mar-2021 | ||
| EP-4314323-A1 | Methods and systems to identify a lung disorder | Pending | 29-Mar-2021 | ||
| US-20240209449-A1 | Methods and systems to identify a lung disorder | Pending | 29-Mar-2021 | ||
| CA-3205172-A1 | Use of immune content scores diagnostically to predict responsiveness of prostate cancer patients to immunotherapy | Pending | 15-Jan-2021 | ||
| US-20240071622-A1 | Clinical classifiers and genomic classifiers and uses thereof | Pending | 03-Dec-2020 | G16H50/30 |
Veracyte Executive Team (33)
| Name | Title | Board Seat |
|---|---|---|
| Bonnie Anderson | Co-founder and Executive Chairwoman | |
| Marc Stapley | Chief Executive Officer & Board Member | |
| Rebecca Chambers | Executive Vice President and Chief Financial Officer | |
| Jonathan Wygant | Chief Accounting Officer, Accounting & Vice President | |
| Phillip Febbo | Chief Medical Officer & Chief Scientific Officer |
Veracyte Board Members (18)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bonnie Anderson | Veracyte | Co-founder and Executive Chairwoman | |
| Eliav Barr | Self | Board Member | |
| Evan Jones | jVEN Capital | Board Member | |
| Fred Cohen Ph.D | Self | Board Member | |
| Jens Holstein | Self | Board Member |
Veracyte Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Veracyte Investments & Acquisitions (5)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| C2i Genomics | 05-Feb-2024 | Decision/Risk Analysis | |||
| HalioDx | 02-Aug-2021 | Diagnostic Equipment | |||
| Decipher Urologic Cancers | 12-Mar-2021 | Diagnostic Equipment | |||
| NanoString Technologies (License of nCounter Diagnostic Assets and Rights) | 03-Dec-2019 | Buildings and Property | |||
| Allegro Diagnostics | 05-Sep-2014 | Merger/Acquisition | Diagnostic Equipment |
Veracyte Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Decipher Urologic Cancers | Diagnostic Equipment | San Diego, CA |
Veracyte ESG
Risk Overview
Risk Rating
Updated April, 13, 2024
22.79 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,009
Rank
Percentile
Healthcare
Industry
of 634
Rank
Percentile
Medical Devices
Subindustry
of 225
Rank
Percentile
Veracyte FAQs
-
When was Veracyte founded?
Veracyte was founded in 2006.
-
Who is the CEO of Veracyte?
Bonnie Anderson and Marc Stapley are the CEOs of Veracyte.
-
Where is Veracyte headquartered?
Veracyte is headquartered in South San Francisco, CA.
-
What is the size of Veracyte?
Veracyte has 815 total employees.
-
What industry is Veracyte in?
Veracyte’s primary industry is Diagnostic Equipment.
-
Is Veracyte a private or public company?
Veracyte is a Public company.
-
What is Veracyte’s stock symbol?
The ticker symbol for Veracyte is VCYT.
-
What is the current stock price of Veracyte?
As of 04-Oct-2024 the stock price of Veracyte is $32.84.
-
What is the current market cap of Veracyte?
The current market capitalization of Veracyte is $2.52B.
-
What is Veracyte’s current revenue?
The trailing twelve month revenue for Veracyte is $400M.
-
Who are Veracyte’s competitors?
Agendia, Foundation Medicine, Centogene, HemoCue, and Asuragen are some of the 23 competitors of Veracyte.
-
What is Veracyte’s annual earnings per share (EPS)?
Veracyte’s EPS for 12 months was -$0.75.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
